2297 (2297) Fair Value & Analysis

Healthcare · Market cap HK$336M

2 2297 2297 · HK

PriceHK$0.2400

Fair ValueHK$0.2000

Upside-16.7%

Quality31/100

Watch 2297 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.1500 – HK$0.2900

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price +20.6% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1940 – HK$0.5000 · fair‑value band HK$0.1500 – HK$0.2900 · the HK$0.2400 price screens above the HK$0.2000 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2297 (2297) currently trades at HK$0.2400, while our model-based Fair Value estimate is HK$0.2000 — implying the stock looks roughly 16.7% overvalued today. We read business quality at 31/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at HK$19.2M. Revenue declined 32.3% year over year. It earns a return on equity of -20.7%. Net debt stands at HK$10.4M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$19.2M

Revenue growth (YoY) -32.3%

Return on equity -20.7%

Free cash flow −HK$79.7M FY2025

Operating margin -443%

EPS (TTM) HK$-0.0300

More key figures

Net debt HK$10.4M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2297 reported revenue of HK$19.2M in FY2025 versus HK$81.2M in FY2021, a compound −30.3%/yr. Reported net income was −HK$77.1M in FY2025.

Revenue −30.3%/yr

FY21 HK$81.2M

FY22 HK$83.6M

FY23 HK$73.2M

FY24 HK$39.8M

FY25 HK$19.2M

Net income

FY21 −HK$634M

FY22 −HK$1.3B

FY23 −HK$116M

FY24 −HK$113M

FY25 −HK$77.1M

Is 2297 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	82.40 MXN	-95%
Abbott Laboratories, ABTT34	R$37.76	R$6.34	-83%
Stryker Corporation S1YK34	R$79.18	R$43.78	-45%
Medtronic plc MDT	$79.27	$73.33	-7%
Boston Scientific Corporation B1SX34	R$247.01	R$234.82	-5%
Edwards Lifesciences Corporation EW	$87.45	$41.02	-53%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2297 (2297) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.2000 versus a price of HK$0.2400 — about −17% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2297?

Our model-based fair value for 2297 is HK$0.2000 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.2400.

What is the quality score of 2297?

2297 has a Quality Score of 31/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2297 (2297)?

2297 reported trailing-twelve-month revenue of about HK$19.2M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2297?

The net profit margin of 2297 is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.